Respiratory Medicine
Clinical research activity is centered on idiopathic pulmonary fibrosis, with attention to progressive lung scarring, breathlessness, and decline in pulmonary function.
- Interstitial lung disease
- Pulmonary fibrosis
- Chronic respiratory impairment
The sponsor’s funded trial portfolio reflects interest in treatment options for patients with fibrotic lung disease in the United States and Europe.
Fibrosis and Tissue Remodeling
Research interest extends to the mechanisms and clinical management of fibrotic progression in the lung, including preservation of respiratory capacity and symptom burden.
- Fibrogenesis
- Extracellular matrix remodeling
- Lung function decline
Work in this area is aligned with evaluating therapies intended for a fibrosis-driven pulmonary disorder.
Clinical Pharmacology
The sponsor’s clinical interests include assessment of safety, tolerability, and efficacy in patients with idiopathic pulmonary fibrosis, with emphasis on treatment suitability in a chronic respiratory setting.
- Dose response
- Therapeutic tolerability
- Patient treatment response
Its research activity is concentrated on clinical evaluation of a lung-directed therapeutic candidate in adults with established fibrotic disease.
